Results 141 to 150 of about 260,711 (183)

Functional Difference of MYC and MYCN in Combined Hepatocellular–Cholangiocarcinoma: Regulation of Differentiation by HNF1B

open access: yesCancer Science, Volume 117, Issue 2, Page 536-547, February 2026.
Combined hepatocellular–cholangiocarcinoma (cHCC‐CCA) is a tumor consisting of a mixture of hepatocellular carcinoma and intrahepatic cholangiocarcinoma (CCA) components, but the mechanisms of development are poorly understood. The activation of Myc may be implicated in the formation of cHCC‐CCA and this work demonstrates for the first time that Myc ...
Masanori Goto   +10 more
wiley   +1 more source

From Genomic and Epigenomic Maps to Medicines in Adult T‐Cell Leukemia/Lymphoma

open access: yesCancer Science, Volume 117, Issue 2, Page 289-296, February 2026.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive and refractory hematologic malignancy that is caused by human T‐cell leukemia virus type‐1 (HTLV‐1) retrovirus. ATL results from a combination of viral latency and the accumulation of abnormalities throughout the genome, epigenome, transcriptome, and signaling pathways.
Kako Suzuki, Makoto Yamagishi
wiley   +1 more source

Microtubule Inhibitors Induce Cross‐Resistance to Osimertinib Through CaMKII Activation in EGFR‐Mutated NSCLC

open access: yesCancer Science, Volume 117, Issue 2, Page 418-428, February 2026.
Eighteen‐week treatment with microtubule inhibitors induces resistance to osimertinib in EGFR‐mutated NSCLC cells. Vinorelbine‐ and paclitaxel‐resistant cells showed activation of FZD7 and CaMKII and increased sensitivity to CaMKII inhibition, with additive or synergistic effects when combined with osimertinib.
Kento Kono   +5 more
wiley   +1 more source

A YAP/TAZ–CDC6 Axis Initiates and Maintains Malignant Transformation

open access: yesCancer Science, Volume 117, Issue 2, Page 353-363, February 2026.
This study demonstrates that constitutive activation of YAP or TAZ is sufficient to induce and maintain malignant transformation in fibroblasts, identifying them as essential oncogenic drivers. Transcriptomic and functional analyses revealed CDC6 as a critical downstream effector of YAP/TAZ, with elevated expression linked to tumorigenesis across ...
David Nduru   +5 more
wiley   +1 more source

MASTL Promotes Hepatocellular Carcinoma Progression and Paclitaxel Resistance Through Mitotic Catastrophe

open access: yesCancer Science, Volume 117, Issue 2, Page 377-392, February 2026.
MASTL drives hepatocellular carcinoma (HCC) progression and paclitaxel resistance by triggering mitotic catastrophe. Depletion of MASTL induces DNA damage and promotes mitotic catastrophe, leading to cell death in HCC. MASTL‐mediated mitotic catastrophe depends on PP2A‐B55α activity, suggesting a novel therapeutic target for overcoming chemotherapy ...
Ke Wang   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy